Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J LORD

Showing results (291-300 of 596) with videos related to

Pageof 60
Sort By:
Molecular Cancer Therapeutics|March 1, 2006
Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatmentBenjamin J Friedmann, Martyn Caplin, Boris Savic, et al.
Breast Cancer Research and Treatment|May 9, 2018
Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016)Benjamin Daniels, Belinda E Kiely, Sarah J Lord, et al.
European Journal of Cancer (Oxford, England : 1990)|August 8, 2007
A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancerS J Lord, W Lei, P Craft, et al.
Journal of the American Chemical Society|June 25, 2008
A photoactivatable push-pull fluorophore for single-molecule imaging in live cellsSamuel J Lord, Nicholas R Conley, Hsiao-lu D Lee, et al.
JCO Precision Oncology|July 6, 2026
Time to Treatment Failure as an End Point in Pragmatic Oncology Trials: Association With Progression-Free Survival Across Randomized StudiesJanene Dalrymple, Rebecca Symons, Katrin M Sjoquist, et al.
Journal of General Internal Medicine|July 26, 2022
Costs of Specialist Referrals From Employer-Sponsored Integrated Health Care Clinics Are Lower Than Those From Community ProvidersJohn R Wright, Divya K Madhusudhan, David C Lawrence, et al.
The Journal of Pathology|August 15, 2009
Conditional deletion of the Lkb1 gene in the mouse mammary gland induces tumour formationAfshan McCarthy, Christopher J Lord, Kay Savage, et al.
JCO Precision Oncology|January 11, 2024
Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized TrialsRachel Woodford, Deborah Zhou, Peey-Sei Kok, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|January 1, 1996
Reduced dose OKT3 prophylaxis in sensitised kidney recipientsC R Darby, R H Moore, B Shrestha, et al.
Transplantation|May 7, 2015
The relative benefits and costs of solid phase bead technology to detect preformed donor specific antihuman leukocyte antigen antibodies in determining suitability for kidney transplantationHung T Do Nguyen, Wai H Lim, Jonathan C Craig, et al.
Pageof 60

Showing results (291-300 of 596) with videos related to

Sort By:
Pageof 60
Molecular Cancer Therapeutics|March 1, 2006
Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatmentBenjamin J Friedmann, Martyn Caplin, Boris Savic, et al.
Breast Cancer Research and Treatment|May 9, 2018
Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016)Benjamin Daniels, Belinda E Kiely, Sarah J Lord, et al.
European Journal of Cancer (Oxford, England : 1990)|August 8, 2007
A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancerS J Lord, W Lei, P Craft, et al.
Journal of the American Chemical Society|June 25, 2008
A photoactivatable push-pull fluorophore for single-molecule imaging in live cellsSamuel J Lord, Nicholas R Conley, Hsiao-lu D Lee, et al.
JCO Precision Oncology|July 6, 2026
Time to Treatment Failure as an End Point in Pragmatic Oncology Trials: Association With Progression-Free Survival Across Randomized StudiesJanene Dalrymple, Rebecca Symons, Katrin M Sjoquist, et al.
Journal of General Internal Medicine|July 26, 2022
Costs of Specialist Referrals From Employer-Sponsored Integrated Health Care Clinics Are Lower Than Those From Community ProvidersJohn R Wright, Divya K Madhusudhan, David C Lawrence, et al.
The Journal of Pathology|August 15, 2009
Conditional deletion of the Lkb1 gene in the mouse mammary gland induces tumour formationAfshan McCarthy, Christopher J Lord, Kay Savage, et al.
JCO Precision Oncology|January 11, 2024
Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized TrialsRachel Woodford, Deborah Zhou, Peey-Sei Kok, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|January 1, 1996
Reduced dose OKT3 prophylaxis in sensitised kidney recipientsC R Darby, R H Moore, B Shrestha, et al.
Transplantation|May 7, 2015
The relative benefits and costs of solid phase bead technology to detect preformed donor specific antihuman leukocyte antigen antibodies in determining suitability for kidney transplantationHung T Do Nguyen, Wai H Lim, Jonathan C Craig, et al.
Pageof 60